<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001966" GROUP_ID="NEONATAL" ID="489899102712425133" MERGED_FROM="" MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Short title (no longer in use): Doxapram for extubating in preterm infants&lt;/p&gt;&lt;p&gt;sent for update Oct/03&lt;br&gt;sent to Jane Bell Nov/04&lt;/p&gt;&lt;p&gt;sent for update Jan 9-06&lt;/p&gt;&lt;p&gt;CL 2/06 (minor update)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-04-18 14:22:24 -0400" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="0010" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton">
<TITLE>Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation</TITLE>
<CONTACT MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton"><PERSON ID="5306" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Diane</FIRST_NAME><LAST_NAME>Haughton</LAST_NAME><POSITION>Managing Editor, Cochrane Neonatal Group</POSITION><EMAIL_1>haughton@mcmaster.ca</EMAIL_1><URL>http://cochrane.mcmaster.ca/neonatal/</URL><ADDRESS><DEPARTMENT>Department of Pediatrics and Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><ADDRESS_2>CRL, Room B102</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8S 4K1</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 ext: 22897</PHONE_1><FAX_1>+1 905 521 5007</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton"><PERSON ID="4691" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Henderson-Smart</LAST_NAME><ADDRESS><DEPARTMENT>(Deceased) Central Clinical School</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Sydney</ORGANISATION><CITY>Sydney</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="17716" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Davis</LAST_NAME><POSITION>Consultant Neonatologist</POSITION><EMAIL_1>pgd@unimelb.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Newborn Research</DEPARTMENT><ORGANISATION>The Royal Women's Hospital</ORGANISATION><ADDRESS_1>20 Flemington Rd</ADDRESS_1><CITY>Parkville</CITY><ZIP>3052</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 83453763</PHONE_1><FAX_1>+61 3 83453789</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-06-08 15:12:37 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 17/01/06&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 10/01/06&lt;/p&gt;" NOTES_MODIFIED="2009-06-08 15:12:37 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="6" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;This review updates the existing review 'Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation', published in The Cochrane Library, Disk Issue 3, 2000. The search strategy has been updated to include the CINAHL database. &lt;br&gt;&lt;br&gt;One abstract was found and has been added to the studies awaiting assessment. &lt;br&gt;&lt;br&gt;The conclusions of this review are unchanged.&lt;/p&gt;" NOTES_MODIFIED="2012-04-18 14:22:24 -0400" NOTES_MODIFIED_BY="Diane Haughton"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton"><DATE DAY="25" MONTH="2" YEAR="2013"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-25 20:00:33 +0000" MODIFIED_BY="Diane Haughton">
<DATE DAY="18" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Contact person changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-18 14:22:11 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-07 12:21:20 -0500" MODIFIED_BY="Diane Haughton">
<DATE DAY="8" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>This updates the review "Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation" published in the Cochrane Database of Systematic Reviews, Issue 2, 2006 (<LINK REF="REF-Henderson_x002d_Smart-2006" TYPE="REFERENCE">Henderson-Smart 2006</LINK>).</P>
<P>The search was updated in May 2009.</P>
<P>No new trials were identified for inclusion.</P>
<P>Updated information has been added to Carrizales 1990, Studies awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-06-08 15:12:45 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-06-05 08:56:06 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>This review updates the existing review 'Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation', published in The Cochrane Library, Disk Issue 3, 2000. The search strategy has been updated to include the CINAHL database.<BR/>
<BR/>One abstract was found and has been added to the studies awaiting assessment.<BR/>
<BR/>The conclusions of this review are unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="5" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NSW Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Prince Alfred Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Women's Hospital, Melbourne</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-12 11:40:56 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-07-26 21:04:22 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-07-26 21:04:22 -0400" MODIFIED_BY="[Empty name]">
<I>Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation</I>
</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-16 09:53:26 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram has not been shown to improve outcomes for babies being weaned off mechanical breathing support.When preterm babies have been on mechanical breathing support in neonatal intensive care, it can be hard to wean them off the machine (tracheal extubation). Using drugs called methylxanthines, or breathing support via the nose (nasal CPAP - continuous positive airways pressure) can help. Doxapram stimulates breathing, and is another drug that is sometimes used around extubation. However, the review of trials found no evidence that doxapram can reduce problems for babies around extubation, and it may cause some adverse effects. Further research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-12 11:37:12 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>When preterm infants have been given intermittent positive pressure ventilation (IPPV) for respiratory failure, weaning from support and tracheal extubation may be difficult. A significant contributing factor is thought to be the relatively poor respiratory effort and tendency to develop hypoventilation and apnea, particularly in very preterm infants. Doxapram stimulates breathing and appears to act via stimulation of both the peripheral chemoreceptors and the central nervous system. This effect might increase the chance of successful tracheal extubation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-13 09:56:49 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effect of doxapram on the use of intubation and IPPV and morbidity in preterm infants being weaned from IPPV and in whom endotracheal extubation is planned. In this regard, how does doxapram compare with standard treatment or with an alternative treatment such as methylxanthine or CPAP? Subgroup analyses were prespecified according to birth weight and/or gestational age, use of co-interventions (methylxanthines or nasal CPAP), and route of administration (intravenous or oral).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-14 09:20:10 -0400" MODIFIED_BY="[Empty name]">
<P>The standard search strategy of the Neonatal Review Group as outlined in The Cochrane Library was used. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Oxford Database of Perinatal Trials, MEDLINE, EMBASE and CINAHL up to May 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-12 11:37:12 -0400" MODIFIED_BY="[Empty name]">
<P>Eligible studies included published trials utilising random or quasi-random patient allocation in which preterm or low birth weight infants being weaned from IPPV were given doxapram compared with standard care or other treatments, to facilitate weaning from IPPV and endotracheal extubation. Trials were independently assessed by the review authors before inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-14 09:17:54 -0400" MODIFIED_BY="[Empty name]">
<P>The standard methods of the Cochrane Collaboration and its Neonatal Review Group were used. Each review author extracted data separately. The results were compared and any differences resolved. The data were synthesized using the standard method of Neonatal Review Group with use of relative risk and risk difference.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two trials involving a total of 85 infants compared doxapram and placebo. In both the individual trials and the meta-analyses there were no significant differences between the doxapram and placebo groups in any of the outcomes (failed extubation, death before discharge, respiratory failure, duration of IPPV, side effects, oxygen at 28 days or oxygen at discharge). There was a trend towards an increase in side effects (hypertension or irritability leading to cessation of treatment) in the doxapram group [summary RR 3.21 (0.53, 19.43). In one of these two trials (Huon 1998) an 'alarming rise in blood pressure' occurred in five infants in the doxapram group and none of the controls, although in only one was treatment withdrawn. One additional trial involving only eight infants compared doxapram with aminophylline, but there were insufficient data for meaningful analysis. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence does not support the routine use of doxapram to assist endotracheal extubation in preterm infants who are eligible for methylxanthine and/or CPAP. The results should be interpreted with caution because the small number of infants studied does not allow reliable assessment of the benefits and harms of doxapram. Further trials are required to evaluate the benefits and harms of doxapram compared with no treatment or with other treatments, such as methylxanthines or CPAP, to evaluate whether it is more effective in infants not responding to these other treatments, and to assess whether the drug is effective when given orally. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-12 11:39:48 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-07-29 11:48:20 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-07-29 11:35:58 -0400" MODIFIED_BY="[Empty name]">
<P>When preterm infants have been given intermittent positive pressure ventilation (IPPV) for respiratory failure, weaning from support and tracheal extubation may be difficult. A significant contributing factor is thought to be the relatively poor respiratory effort and tendency to develop hypoventilation and apnea, particularly in very preterm infants (reviewed by <LINK REF="REF-Bancalari-1992" TYPE="REFERENCE">Bancalari 1992</LINK>; <LINK REF="REF-Henderson_x002d_Smart-1995" TYPE="REFERENCE">Henderson-Smart 1995</LINK>).</P>
<P>Weaning from support may be prolonged or, if extubation is achieved, frequent episodes of apnea may occur in association with respiratory failure (hypercarbia, hypoxaemia and acidosis) of sufficient severity as to lead to re-intubation and the use of IPPV. As a consequence, the use of IPPV is prolonged with associated costs for higher dependency care and a potential for morbidity from the intervention. Systematic reviews have suggested that methylxanthines (<LINK REF="REF-Henderson_x002d_Smart-2003" TYPE="REFERENCE">Henderson-Smart 2003</LINK>) and nasal continuous positive airways pressure (CPAP) (<LINK REF="REF-Davis-2003" TYPE="REFERENCE">Davis 2003</LINK>) may assist weaning from IPPV and endotracheal extubation.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-07-29 11:45:44 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram hydrochloride is a respiratory stimulant (an analeptic agent). It can be administered either intravenously (IV) or orally, although in intubated infants, IV would be most likely.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-07-13 10:03:44 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram stimulates breathing and appears to act via stimulation of both the peripheral chemoreceptors and the central nervous system (<LINK REF="REF-Blanchard-1992" TYPE="REFERENCE">Blanchard 1992</LINK>; <LINK REF="REF-Barrington-1986" TYPE="REFERENCE">Barrington 1986</LINK>). This effect might increase the chance of successful tracheal extubation on its own or in combination with other treatments, such as methylxanthines or CPAP. Short term side effects (reviewed by <LINK REF="REF-Blanchard-1992" TYPE="REFERENCE">Blanchard 1992</LINK>) such as hypertension, excessive central nervous system stimulation, gastrointestinal disturbances with oral use (<LINK REF="REF-Tay_x002d_Uyboco-1991" TYPE="REFERENCE">Tay-Uyboco 1991</LINK>) and heart block (<LINK REF="REF-De-Villiers-1998" TYPE="REFERENCE">De Villiers 1998</LINK>) have been reported.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-07-29 11:48:20 -0400" MODIFIED_BY="[Empty name]">
<P>This updates the review "Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation" published in The Cochrane Library, Issue 2, 2006 (<LINK REF="REF-Henderson_x002d_Smart-2006" TYPE="REFERENCE">Henderson-Smart 2006</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-14 09:18:33 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effect of doxapram on the use of intubation and IPPV and morbidity in preterm infants being weaned from IPPV and in whom endotracheal extubation is planned. In this regard, how does doxapram compare with standard treatment or with an alternative treatment such as methylxanthine or CPAP?</P>
<P>Prespecified subgroup analyses:</P>
<OL>
<LI>Birth weight (greater or less than about 1 kg) and/or gestational age (greater or less than about 28 weeks) subgroups, as the baseline failure rate is likely to be higher in infants born at lower weights and gestational ages</LI>
<LI>Routine use, or not, of co-interventions (methylxanthines or nasal CPAP) as this would lower the baseline rate of failure</LI>
<LI>Administration route (intravenous or oral) as drug levels achieved and side effects may be different</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-12 11:37:59 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-14 09:19:00 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All published trials utilising random or quasi-random patient allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Preterm or low birth weight infants being weaned from IPPV and in whom endotracheal extubation is planned.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Doxapram compared with control (placebo or no treatment), and doxapram compared with an alternative treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-14 09:19:00 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-14 09:19:00 -0400" MODIFIED_BY="[Empty name]">
<P>Failed extubation (unable to wean from IPPV and extubate, or re-intubation for IPPV) within about one week.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-13 10:28:36 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death before discharge</LI>
<LI>Duration of IPPV</LI>
<LI>Side effects leading to cessation of therapy (tachycardia, agitation, seizures, hypertension or feed intolerance)</LI>
<LI>Chronic lung disease (oxygen requirement at about 28 days and at about 36 weeks postmenstrual age)</LI>
<LI>Reduced somatic growth (weight, length and head circumference) and delayed neurodevelopment (more than 2 SDs below the mean on a standard developmental assessment, or abnormal neurological signs) during infancy and childhood</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-12 11:37:36 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-07-13 10:00:03 -0400" MODIFIED_BY="[Empty name]">
<P>The standard search strategy of the Neonatal Review Group as outlined in The Cochrane Library was used. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2009), MEDLINE (1966 - May 2009), CINAHL (1982 - May 2009) and EMBASE (1988 - May 2009). The text term 'doxapram' and MeSH term 'infant, premature' were used in these searches.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-12 11:37:36 -0400" MODIFIED_BY="[Empty name]">
<P>Also searched were previous reviews including cross references, and abstracts published in the program issues of the Society for Pediatric Research 1996 - 2009 and the European Society for Pediatric Research, 1995 - 2005. Expert informants were also consulted.</P>
<P>Clinical trials registries were also searched for ongoing or recently completed trials (clinicaltrials.gov; controlled-trials.com; and who.int/ictrp).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-12 11:37:59 -0400" MODIFIED_BY="[Empty name]">
<P>The standard method of the Cochrane Neonatal Review Group were employed.</P>
<STUDY_SELECTION MODIFIED="2009-07-29 11:35:58 -0400" MODIFIED_BY="[Empty name]">
<P>The title and abstract of each retrieved report was examined to assess eligibility. If there was uncertainty, the full paper was examined. All randomised and quasi-randomized controlled trials fulfilling the selection criteria described in the previous section were included.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-14 09:20:38 -0400" MODIFIED_BY="[Empty name]">
<P>Each review author extracted data separately. The results were compared and any differences resolved.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-12 11:37:47 -0400" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the studies were assessed using the following key criteria: allocation concealment (blinding of randomizations), blinding of intervention, completeness of follow-up, and blinding of outcome measurement/assessment. For each criteria, assessment was yes, no, can't tell. All three review authors separately assessed each study. Any disagreement was resolved by discussion.</P>
<P>In addition, the Risk of Bias table was completed.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-13 10:23:39 -0400" MODIFIED_BY="[Empty name]">
<P>Statistical analyses was performed using Review Manager software. Categorical data was analyzed using relative risk (RR), risk difference (RD) and the number needed to treat (NNT). Continuous data was analyzed using weighted mean difference (WMD). The 95% Confidence interval (CI) was reported on all estimates.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-08-12 11:37:59 -0400" MODIFIED_BY="[Empty name]">
<P>We estimated the treatment effects of individual trials and examined heterogeneity between trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I<SUP>2</SUP> statistic. If we detected statistical heterogeneity, we planned to explore the possible causes (for example, differences in study quality, participants, intervention regimens, or outcome assessments) using <I>post hoc</I> sub group analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-13 10:26:35 -0400" MODIFIED_BY="[Empty name]">
<P>The data were synthesized using the standard method of Neonatal Review Group using Review Manager software (RevMan 5), supplied by the Cochrane Collaboration. This included estimates of typical relative risk and risk difference using the Mantel-Haenszel method. For measured quantities, we used the inverse variance method. All meta-analyses were to be done using the fixed effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-14 09:11:04 -0400" MODIFIED_BY="[Empty name]">
<P>Prespecified subgroup analyses:</P>
<OL>
<LI>Birth weight (greater or less than about 1kg) and/or gestational age (greater or less than about 28 weeks) subgroups, as the baseline failure rate is likely to be higher in infants born at lower weights and gestational ages</LI>
<LI>Routine use, or not, of co-interventions (methylxanthines or nasal CPAP) as this would lower the baseline rate of failure</LI>
<LI>Administration route (intravenous or oral) as drug levels achieved and side effects may be different</LI>
</OL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-12 11:38:31 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-08-12 11:36:39 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Doxapram vs standard treatment</B>
</P>
<P>Two eligible trials were found. <LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> enrolled 56 preterm infants less than three weeks of age with birth weights less than 1251 g and gestational age less than 30 (mean 25 - 26) weeks, while <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> enrolled 29 preterm infants less than six days of age with birth weights less than 1250 g and gestational age less than 34 (mean 29 - 30) weeks. Treatment groups were well matched at entry in the <LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> trial. In <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> the doxapram group had a significantly lower birth weight and more male infants, and showed clinically important trends to higher gestational age and more small for gestational age infants.</P>
<P>
<LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> used a loading dose of 3.5 mg/kg followed by 1 mg/kg/hr, whereas <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> had no loading dose of doxapram and the initial infusion rate was lower at 0.5 mg/kg/hr, with option of doubling if there was failure to respond . Both trials enrolled infants being weaned from IPPV although the amount of ventilatory support in <LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> was greater (FiO2 &lt; 0.4, rate &lt; 30, peak inspiratory pressure &lt; 26 cms H2O) than in <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> (FiO2 &lt; 0.26, rate &lt; 16, peak inspiratory pressure &lt; 10 cms H2O).</P>
<P>
<LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> loaded infants with IV aminophylline during weaning of IPPV; then, one and a half days later on average, each infant was extubated to nasal CPAP for 72 hours. <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> loaded infants with caffeine eight hours prior to attempted extubation, after which CPAP was allowed if there was deterioration in respiratory function.</P>
<P>
<B>Doxapram vs. an alternative treatment</B>
</P>
<P>One small pilot study of doxapram vs. aminophylline in eight infants was found (<LINK REF="STD-Eyal-1985" TYPE="STUDY">Eyal 1985</LINK>).</P>
<P>One study comparing doxapram vs. theophylline was found in abstract form (<LINK REF="STD-Carrizales-1990" TYPE="STUDY">Carrizales 1990</LINK>) and is awaiting further assessment pending more information from an author.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-29 11:51:54 -0400" MODIFIED_BY="[Empty name]">
<P>Both trials evaluating doxapram vs. control are of high quality in terms of blinding of randomization, intervention and outcome assessment, as well as completeness of follow-up. The one small trial comparing doxapram with aminophylline is of insufficient size for meaningful analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-12 11:38:31 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Doxapram vs. standard care (Comparison 1):</B>
</P>
<P>In both the individual trials and the meta-analyses there were no significant differences between the doxapram and placebo groups in any of the outcomes [failed extubation, death before discharge, side effects, oxygen at 28 days or oxygen at discharge (Outcomes 1.1, 1.2, 1.4. 1.5, 1.6)]. The data on 'failed extubation' (unable to extubate or reintubated within about one week) from <LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> were confounded by the use of open label doxapram in four control infants with severe apnea after extubation and so could not be used. There was no difference in the duration of IPPV between the doxapram and placebo groups in either trial or in the meta-analysis (Outcome 1.3).</P>
<P>There was a trend towards an increase in side effects (hypertension or irritability leading to cessation of treatment) in the doxapram group [summary RR 3.21 (0.53, 19.43)] (Outcome 1.4). In <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> an 'alarming rise in blood pressure' occurred in five infants in the doxapram group and none of the controls, although in only one was treatment withdrawn.</P>
<P>Respiratory failure without the use of reintubation was not a prespecified outcome. <LINK REF="STD-Barrington-1998" TYPE="STUDY">Barrington 1998</LINK> reported that apnea was a cause of failure in fewer of the doxapram (4/12) compared with the placebo group (12/14). <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> also noted more apnea in the placebo group but this was only so for moderate apnea (&gt; 10 sec. with bradycardia &lt; 80 bpm for &lt; 30 secs) and not for severe apnea (bradycardia &gt; 30 sec).</P>
<P>There were no trial data as to the effect of doxapram without use of methylxanthine and/or CPAP, so the prespecified subgroup analysis of trials by use, or not, of co-interventions was not possible. Subgroup analyses by birth weight, gestational age or route of administration could not be carried out as the required data were not reported. No study reported later growth or development in the infants.</P>
<P>
<B>Doxapram vs. aminophylline (Comparison 2):</B>
</P>
<P>In the only trial (<LINK REF="STD-Eyal-1985" TYPE="STUDY">Eyal 1985</LINK>), six infants were randomised to doxapram and four failed extubation, while two received aminophylline and both failed to be extubated.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-12 11:39:48 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Doxapram vs. standard care</B>
</P>
<P>Both the trials eligible for this review used doxapram as an addition to standard measures [methylxanthines (<LINK REF="REF-Henderson_x002d_Smart-2003" TYPE="REFERENCE">Henderson-Smart 2003</LINK>) and nasal CPAP (<LINK REF="REF-Davis-2003" TYPE="REFERENCE">Davis 2003</LINK>)] known to assist endotracheal extubation in preterm infants. In this setting doxapram did not appear to provide additional assistance. Observational studies suggest that doxapram could be useful in preterm infants who cannot be extubated despite standard treatments such as methylxanthines and CPAP (<LINK REF="REF-Barrington-1986" TYPE="REFERENCE">Barrington 1986</LINK>). This has not been examined in a randomised controlled trial.</P>
<P>The <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> trial was stopped because the baseline rate of failed extubation in the control group was much lower than the rate prior to commencing the trials. They attribute this to the introduction of a standard protocol for endotracheal extubation.</P>
<P>The trend towards increased side effects including hypertension is consistent with observational studies (<LINK REF="REF-Blanchard-1992" TYPE="REFERENCE">Blanchard 1992</LINK>). The <LINK REF="STD-Huon-1998" TYPE="STUDY">Huon 1998</LINK> trial emphasized this and reported higher blood levels despite lower dosage when doxapram was given in the first few days of life.</P>
<P>
<B>Doxapram vs. aminophylline</B>
</P>
<P>There are insufficient data available for any conclusions to be made.</P>
<P>One additional study (<LINK REF="STD-Carrizales-1990" TYPE="STUDY">Carrizales 1990</LINK>), reported in abstract form, is awaiting assessment. It compared doxapram and theophylline and it reported that twelve infants were randomised to doxapram and two failed extubation (undefined), while thirteen infants were randomised to theophylline and five failed extubation. This study requires author clarification which is being sought.</P>
<P>One observational study has suggested an association between the total dose and duration of doxapram treatment and isolated mental developmental delay in infants weighing less than 1250 grams at birth (<LINK REF="REF-Sreenan-2001" TYPE="REFERENCE">Sreenan 2001</LINK>). As discussed by the authors, they could not control for the severity of apnea, which has also been associated with poor neurodevelopmental outcome (<LINK REF="REF-Cheung-1999" TYPE="REFERENCE">Cheung 1999</LINK>).</P>
<P>Another suggested source of toxicity is benzyl alcohol used in the intravenous preparation of doxapram in the USA. It has been pointed out that the <LINK REF="REF-Sreenan-2001" TYPE="REFERENCE">Sreenan 2001</LINK> observations were made in Canada where doxapram does not contain benzyl alcohol (<LINK REF="REF-Finer-2002" TYPE="REFERENCE">Finer 2002</LINK>).</P>
<P>This information suggests that new trials need to evaluate neurological development.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-13 10:09:28 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-13 10:09:28 -0400" MODIFIED_BY="[Empty name]">
<P>The evidence does not support the routine use of doxapram to assist endotracheal extubation in preterm infants who are eligible to receive methylxanthine and/or CPAP. There are no data on the effects of doxapram vs. control in the absence of use of methylxanthine or CPAP. The results should be interpreted with caution because the small number of infants studied does not allow reliable assessment of the benefits and harms of doxapram.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further trials are required to evaluate the benefits and harms of doxapram compared with no treatment or with other treatments such as methylxanthines or CPAP. Trials could also evaluate whether it is effective in infants not responding to these other treatments. Doxapram would be a more useful drug if it were effective when given orally although no randomised controlled trials have evaluated its use by this route. </P>
<P>Any future trials should include important outcomes including long term growth and development.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-12 11:40:56 -0400" MODIFIED_BY="[Empty name]">
<P>The Cochrane Neonatal Review Group has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-14 09:14:00 -0400" MODIFIED_BY="[Empty name]">
<P>Each review author independently evaluated the trials for quality and extracted the data. <BR/>DHS double entered the data and wrote the text of the review. <BR/>DHS has updated the review with assistance from co-author Peter Davis.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-12 11:45:49 -0400" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrington-1998" NAME="Barrington 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrington KJ, Muttitt SC</AU>
<TI>Randomized, controlled, blinded trial of doxapram for extubation of the very low birthweight infant</TI>
<SO>Acta Pediatrica</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>191-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00218580"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eyal-1985" NAME="Eyal 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eyal FG, Sagi EF, Alpan G, Glaick B Arad I</AU>
<TI>Aminophylline versus doxapram in weaning premature infants from mechanical ventilation: preliminary report</TI>
<SO>Critical Care Medicine</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huon-1998" NAME="Huon 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huon C, Moriette G, Mussat P, Parat S, Relier JP</AU>
<TI>Use of preestablished criteria for deciding on extubation in the very low birthweight newborn. Preliminary analysis of a randomized controlled study</TI>
<SO>Biology of the Neonate</SO>
<YR>1993</YR>
<VL>63</VL>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huon C, Moriette G, Mussat P, Parat S, Rey E, Relier JP</AU>
<TI>Treatment of very low birth weight infants with a low dose of doxapram associated with caffeine: effects on weaning from mechanical ventilation</TI>
<SO>Proceedings of the 14th European Congress of Perinatal Medicine</SO>
<YR>1994</YR>
<PG>81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huon C, Rey E, Mussat P, Parat S, Moriette G</AU>
<TI>Low-dose doxapram for treatment of apnoea following early weaning in low birthweight infants: a randomized, double-blind study</TI>
<SO>Acta Pediatrica</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>1180-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrizales-1990" NAME="Carrizales 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrizales E, Karna P, Dolanski E</AU>
<TI>Doxapram vs theophylline in weaning infants from low ventilation</TI>
<SO>Pediatric Research</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>201A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-12 11:45:49 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-12 11:45:49 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bancalari-1992" NAME="Bancalari 1992" NOTES="&lt;p&gt;Bancalari E, Sinclair JC. Mechanical ventilation. In: Sinclair JC, Bracken MB, eds; Effective care of the newborn infant. New York: Oxford University Press, 1992, pp200-220.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Bancalari E, Sinclair JC</AU>
<TI>Mechanical ventilation</TI>
<SO>Effective care of the newborn infant</SO>
<YR>1992</YR>
<PG>200-20</PG>
<ED>Sinclair JC, Bracken MB</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrington-1986" NAME="Barrington 1986" NOTES="&lt;p&gt;Barrington KJ, Finer NN, Peters KL, Barton J. Physiological effects of doxapram in idiopathic apnea of prematurity. J Pediatr 1986; 108:125-129&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Barrington KJ, Finer NN, Peters KL, Barton J</AU>
<TI>Physiological effects of doxapram in idiopathic apnea of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1986</YR>
<VL>108</VL>
<PG>125-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blanchard-1992" NAME="Blanchard 1992" NOTES="&lt;p&gt;Blanchard PW, Aranda JV, Pharmacotherapy of respiratory control disorders. In:Beckerman RC, Brouillette RT, Hunt CE (eds), Respiratory Control Disorders in Infants and Children. Baltimore: Williams &amp;amp; Wilkins 1992, pp.161-177.&lt;br&gt;&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Blanchard PW, Aranda JV,</AU>
<TI>Pharmacotherapy of respiratory control disorders</TI>
<SO>Respiratory Control Disorders in Infants and Children</SO>
<YR>1992</YR>
<PG>161-77</PG>
<ED>Beckerman RC, Brouillette RT, Hunt CE</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-1999" MODIFIED="2009-08-12 11:45:32 -0400" MODIFIED_BY="[Empty name]" NAME="Cheung 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cheung PY, Barrington KJ, Finer NN, Robertson CM</AU>
<TI>Early childhood neurodevelopment in very low birth weight infants with predischarge apnea</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>27</VL>
<PG>14-20</PG>
<IDENTIFIERS MODIFIED="2009-08-12 11:45:25 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2003" MODIFIED="2008-10-16 09:57:12 -0400" MODIFIED_BY="[Empty name]" NAME="Davis 2003" NOTES="&lt;p&gt;Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants (Cochrane Review). In: The Cochrane Library, &lt;br&gt;Issue 4, 1999. Oxford: Update Software. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 09:57:12 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Davis PG, Henderson-Smart DJ</AU>
<TI>Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-16 09:57:00 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 09:57:00 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000143"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Villiers-1998" NAME="De Villiers 1998" NOTES="&lt;p&gt;De Villiers GS, Walele A, Van der Merwe P-L, et al. Second-degree atrioventricular heart block after doxapram administration. J Pediatr 1998; 133:149-150&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>De Villiers GS, Walele A, Van der Merwe PL, Kalis NN</AU>
<TI>Second-degree atrioventricular heart block after doxapram administration</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>133</VL>
<PG>149-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-2002" MODIFIED="2009-06-01 20:53:17 -0400" MODIFIED_BY="[Empty name]" NAME="Finer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Finer NN, Barrington KJ</AU>
<TI>Doxapram and neurodevelopmental outcome (Letter)</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<PG>296</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-1995" NAME="Henderson-Smart 1995" NOTES="&lt;p&gt;Henderson-Smart DJ. Recurrent apnoea. In: Bailliere's Clinical Paediatrics. Vol 3 No. 1 Pulmonary Problems in the Perinatal Period and their Sequelae. Ed Yu VYH, Bailliere Tindall, London, 1995 pp203-222.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Henderson-Smart DJ</AU>
<TI>Recurrent apnoea</TI>
<SO>Bailliere's Clinical Paediatrics</SO>
<YR>1995</YR>
<VL>3, No. 1. Pulmonary problems in the perinatal period and their sequelae</VL>
<PG>203-22</PG>
<ED>Ed Yu VYH</ED>
<PB>Bailliere Tindall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2003" MODIFIED="2008-10-16 09:58:25 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2003" NOTES="&lt;p&gt;Henderson-Smart DJ, Davis PG. Prophylactic methylxanthine for extubation in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 1999. Oxford: Update Software. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 09:58:25 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Davis PG</AU>
<TI>Prophylactic methylxanthines for extubation in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-16 09:58:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 09:58:25 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sreenan-2001" MODIFIED="2009-08-12 11:45:49 -0400" MODIFIED_BY="[Empty name]" NAME="Sreenan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sreenan C, Etches PC, Demianczuk N, Robertson CMT</AU>
<TI>Isolated mental developmental delay in low birth weight infants: assosciation with prolonged doxapram therapy for apnea</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<PG>832-837</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tay_x002d_Uyboco-1991" NAME="Tay-Uyboco 1991" NOTES="&lt;p&gt;Tay-Uyboco J, Kwiatkowski K, Cates DB, et al. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol Neonate 1991; 59:190-200&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tay-Uyboco J, Kwiatkowski K, Cates DB, Seifert B, Hasan SU, Rigatto H</AU>
<TI>Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity</TI>
<SO>Biology of the Neonate</SO>
<YR>1991</YR>
<VL>59</VL>
<PG>190-200</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-06-05 09:01:57 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Henderson_x002d_Smart-2000" MODIFIED="2008-10-16 10:00:14 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2000" TYPE="COCHRANE_REVIEW">
<AU>Hennderson-Smart D, Davis PG</AU>
<TI>Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-16 09:59:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 09:59:25 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001966"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2006" MODIFIED="2009-06-05 09:01:55 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2006" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart D, Davis PA</AU>
<TI>Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-06-05 09:01:55 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-05 09:01:47 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001966"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-12 11:44:56 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-12 11:44:03 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-12 11:43:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barrington-1998">
<CHAR_METHODS MODIFIED="2009-08-12 11:43:48 -0400" MODIFIED_BY="[Empty name]">
<P>Blinding of randomizations - yes; blinding of intervention - yes; complete follow up - yes; blinding of outcome assessment - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 11:36:46 -0400" MODIFIED_BY="[Empty name]">
<P>56 infants (27 treatment and 29 control) weight &lt;1251 g and gestation &lt;30 weeks at birth; less than 3 weeks old and in FiO2 &lt;0.4 and ventilator rate &lt; 30 and peak insp. pressure &lt; 26 cms H2O.<BR/>Exclusion criteria not given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 11:43:43 -0400" MODIFIED_BY="[Empty name]">
<P>IV doxapram 3.5 mg/kg over 20 mins, then infusion of 1 mg/kg/hr.<BR/>Placebo was saline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 11:43:39 -0400" MODIFIED_BY="[Empty name]">
<P>Death before discharge; Failed extubation - not extubated or reintubation within 3 days Respiratory failure; apnoea &gt; 3 in 12 hrs or PaCO2 &gt; 60 mm Hg or FiO2 &gt;80 to keep PaO2 &gt;60; side effects; oxygen therapy at discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 11:43:39 -0400" MODIFIED_BY="[Empty name]">
<P>All extubated to nasal prong CPAP (6 cms H2O) for 72 hrs when vent rate 6 for 12 hrs and FiO2 &lt; 0.45; all given aminopylline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 11:42:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eyal-1985">
<CHAR_METHODS MODIFIED="2009-08-12 11:38:31 -0400" MODIFIED_BY="[Empty name]">
<P>Randomization not mentioned - double blind, numerically coded drugs - by pharmacy; blinding of treatment - yes; completeness of follow-up - yes; blinding of outcome assessment - yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 11:36:50 -0400" MODIFIED_BY="[Empty name]">
<P>8 preterm infants (6 treatment and 2 control) recovering from RDS, unable to wean ventilator rate over 24 hrs. Mean gestational age 30 weeks, birthweight 1215 g.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-26 19:22:41 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram 2.5 mg/kg/hr vs aminophylline 6 mg/kg load and 1.5 mg/kg/8hr IV.<BR/>Each given for 48 hrs. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 11:42:23 -0400" MODIFIED_BY="[Empty name]">
<P>Failed to wean from ventilation, failed to extubate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Infants who failed were given the alternative treatment after 48 hrs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 11:44:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huon-1998">
<CHAR_METHODS MODIFIED="2009-08-12 11:44:03 -0400" MODIFIED_BY="[Empty name]">
<P>Blinding of randomization - yes; blinding of intervention - yes; complete followup - yes; blinding of outcome assessment - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 11:43:17 -0400" MODIFIED_BY="[Empty name]">
<P>29 infants who required mechanical ventilation up to 21 days (14 treatment and 15 control) weight &lt; 1250 grams and gestational age &lt; 34 weeks at birth; and &lt; 6 days old; and on IPPV but never needed more than FiO2 0.3; at entry FiO2 &lt; 0.25, IMV &lt;16, PIP &lt;10, normal chest xray.<BR/>Excluded - congenital abnormality, severe brain lesion (IVH &gt; grade 2, white matter densities), PDA with L to R shunt, uncontrolled infection or metabolic disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 11:43:10 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram IV 0.5 mg/kg/hr, dose could be doubled if no response.<BR/>Placebo was normal saline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death before discharge; failed extubation (could not be extubated or reintubated within 5 days); side effects;<BR/>oxygen therapy at 28 days; apnea; IVH or PVL; infection; NEC; ROP;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 11:43:04 -0400" MODIFIED_BY="[Empty name]">
<P>All infants given caffeine citrate (20 mg/kg load and 5 mg/kg/ day). Nasal CPAP could be used (number not given). Extubation was carried out 8 hrs after starting doxapram / placebo if possible.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CPAP = continuous positive airways pressure; IPPV = intermittent positive pressure ventilation; IVH = intraventricular haemorrhage; PVL = periventricular leukomalacia; NEC = necrotizing enterocolitis; ROP = retinopathy of prematurity.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-08-12 11:44:56 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-08-12 11:44:56 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carrizales-1990">
<CHAR_METHODS MODIFIED="2009-08-12 11:44:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized - method unknown.</P>
<P>Blinding of treatment - unknown.</P>
<P>Completeness of follow up - unknown.</P>
<P>Blinding of outcome assessment - unknown.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 11:44:49 -0400" MODIFIED_BY="[Empty name]">
<P>25 very low birth weight infants (700 - 1500 grams), mean age 61 +/- 58 hrs.</P>
<P>Ready to wean from mechanical ventilation (inspired oxygen &lt; or equal to 30%, mean airway pressure 10 -15 cms H<SUB>2</SUB>O, positive inspiratory pressure &lt; or equal to 18 cms H<SUB>2</SUB>O).</P>
<P>12 infants in the doxapram group and 13 in the theophylline group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-01 07:46:05 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram incremental doses of 0.5 to 2.5 mg/kg/hr IV</P>
<P>Theophylline loading dose of 6 mg/kg and maintenance dose of 2 mg.kg/8 hrs IV.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 11:44:56 -0400" MODIFIED_BY="[Empty name]">
<P>Failed extubation during 7 day trial period.</P>
<P>Side effects - hypertension, seizures, tachycardia or intracranial hemorrage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-01 07:40:43 -0400" MODIFIED_BY="[Empty name]">
<P>Only published as abstract.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-12 11:43:35 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-12 11:43:21 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-29 11:39:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrington-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 11:43:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eyal-1985">
<DESCRIPTION>
<P>Randomization not mentioned - double blind, numerically coded drugs - by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 11:42:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huon-1998">
<DESCRIPTION>
<P>Randomization mentioned but details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-12 11:43:00 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-12 11:41:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrington-1998">
<DESCRIPTION>
<P>Blinding of randomizations - yes</P>
<P>Blinding of intervention - yes</P>
<P>Blinding of outcome assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-30 00:23:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eyal-1985">
<DESCRIPTION>
<P>Stated blinding of initial treatment but not of blinding later outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-12 11:43:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huon-1998">
<DESCRIPTION>
<P>Blinding of randomization, treatment and outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-08-12 11:43:35 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-12 11:43:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrington-1998">
<DESCRIPTION>
<P>Complete follow up - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-12 11:43:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eyal-1985">
<DESCRIPTION>
<P>Completeness of follow-up - yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-12 11:43:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huon-1998">
<DESCRIPTION>
<P>Complete follow up - yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-12 11:42:08 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 11:42:08 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barrington-1998">
<DESCRIPTION>
<P>One infant in the control group was accidentally given doxapram and included in the control analysis and publication because it was in the intention group due to randomization. A re-analysis with it in the doxapram group made no difference to the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eyal-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-29 11:41:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huon-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-12 11:42:46 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-26 19:14:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrington-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 11:42:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eyal-1985">
<DESCRIPTION>
<P>The trial had very small numbers. Failing in the assigned group led to change over to the alternative treatment. This included one in doxapram group and three in the aminophylline group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-26 19:32:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huon-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-26 20:33:26 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-26 20:33:26 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Doxapram vs control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.971656615371363" CI_START="0.21729530844048453" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4729986238418056" LOG_CI_START="-0.662949650303519" LOG_EFFECT_SIZE="-0.09497551323085672" METHOD="MH" MODIFIED="2009-07-26 20:33:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7431072698051624" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.3277413058015213">
<NAME>Failed extubation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.971656615371363" CI_START="0.21729530844048453" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4729986238418056" LOG_CI_START="-0.662949650303519" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="147" O_E="0.0" SE="0.6672616392676078" STUDY_ID="STD-Huon-1998" TOTAL_1="14" TOTAL_2="15" VAR="0.4452380952380952" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06342444698534958" CI_END="6.00961646021892" CI_START="0.34077776817902006" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4310638297872342" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="100.0" ID="CMP-001.02" LOG_CI_END="0.7788467557755003" LOG_CI_START="-0.4675287456897015" LOG_EFFECT_SIZE="0.15565900504289937" METHOD="MH" MODIFIED="2008-10-16 09:59:40 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8011631124833907" P_Q="0.0" P_Z="0.6244472782697906" Q="5.748935766659609E-33" RANDOM="NO" SCALE="18.793394899921513" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" WEIGHT="100.0" Z="0.48955718945818727">
<NAME>Death before discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.913958983993496" CI_START="0.2911926134063053" EFFECT_SIZE="1.6111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9500706314254688" LOG_CI_START="-0.5358196458341685" LOG_EFFECT_SIZE="0.20712549279565004" ORDER="148" O_E="0.0" SE="0.8728193041378076" STUDY_ID="STD-Barrington-1998" TOTAL_1="27" TOTAL_2="29" VAR="0.7618135376756067" WEIGHT="66.63829787234043"/>
<DICH_DATA CI_END="15.539663588267699" CI_START="0.07387284654863233" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1914416127055376" LOG_CI_START="-1.1315151659506513" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="149" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Huon-1998" TOTAL_1="14" TOTAL_2="15" VAR="1.861904761904762" WEIGHT="33.361702127659576"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.012987514978160896" CI_END="2.127892300029501" CI_START="-2.8519230680709375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3620153840207181" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-10-16 09:59:45 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9092673011705081" P_Q="1.0" P_Z="0.7756707811481076" Q="0.0" RANDOM="NO" SCALE="7.170538904619482" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.2849652294641996">
<NAME>Days of IPPV</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4087241180167798" CI_START="-3.0087241180167794" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.9" ORDER="150" SD_1="4.5" SD_2="5.8" SE="1.3820274961085253" STUDY_ID="STD-Barrington-1998" TOTAL_1="27" TOTAL_2="29" WEIGHT="84.49615399482046"/>
<CONT_DATA CI_END="5.623587356660834" CI_START="-7.023587356660834" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.0" ORDER="151" SD_1="10.0" SD_2="7.0" SE="3.2263793654069586" STUDY_ID="STD-Huon-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="15.503846005179545"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.2605662184164685E-5" CI_END="19.434256520762023" CI_START="0.5317888345683979" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.214797136038186" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.2885679308635227" LOG_CI_START="-0.2742607853501422" LOG_EFFECT_SIZE="0.5071535727566903" METHOD="MH" NO="4" P_CHI2="0.9971671604228354" P_Q="1.0" P_Z="0.20335328725211876" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" WEIGHT="100.0" Z="1.2720558906060313">
<NAME>Side effects causing cessation of therapy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.128238115570028" CI_START="0.35644847478202957" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4643142161818417" LOG_CI_START="-0.4480032392625791" LOG_EFFECT_SIZE="0.5081554884596312" ORDER="152" O_E="0.0" SE="1.123304739452125" STUDY_ID="STD-Barrington-1998" TOTAL_1="27" TOTAL_2="29" VAR="1.2618135376756066" WEIGHT="66.5871121718377"/>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" ORDER="153" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Huon-1998" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="33.41288782816229"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.6230071114122" CI_START="0.14100214804229516" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041249" LOG_EFFECT_SIZE="0.505149978319906" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4652770182299425" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.7301851594185668">
<NAME>Oxygen at 28 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" ORDER="154" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Huon-1998" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9877430905368765" CI_START="0.38517301538862836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.29836025250989207" LOG_CI_START="-0.4143441464652655" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" MODIFIED="2008-10-16 09:59:58 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.749756781930899" Q="0.0" RANDOM="NO" SCALE="2.757506934078277" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.3189600839648651">
<NAME>Oxygen at discharge in survivors</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9877430905368765" CI_START="0.38517301538862836" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.29836025250989207" LOG_CI_START="-0.4143441464652655" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="155" O_E="0.0" SE="0.41864609190168045" STUDY_ID="STD-Barrington-1998" TOTAL_1="24" TOTAL_2="27" VAR="0.17526455026455026" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>